Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

EyePoint Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm

September 1, 2022 GMT

Investors cancontactthe law firm at no cost to learn more about recovering their losses

​LOS ANGELES, Sept. 01, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises EyePoint Pharmaceuticals, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. EyePoint investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email:, to discuss their legal rights, or click here to join the case via The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

On August 30, 2022, after market hours, EyePoint disclosed that it had received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts seeking documents regarding sales practices for its postoperative inflammation treatment, DEXYCU.


On this news, EyePoint’s stock fell as much as 20% during after-hours trading on August 30, 2022, thereby injuring investors.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising